Subscribe to RSS
DOI: 10.1055/a-1508-3912
Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study
Funding Intego is funded regularly by the Flemish Government (Ministry of Health and Welfare). We hereby state the independence of the researchers from the funders. This study was supported by an unrestricted educational grant from Novo Nordisk.
Abstract
Aims This study aims to assess the prevalence of atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), chronic kidney disease (CKD), and their combined presence in type 2 diabetes (T2D) patients in primary care for whom the 2019 ADA/EASD consensus update “Management of Hyperglycemia in Type 2 Diabetes” recommends GLP-1 receptor agonists (GLP-1RA) or sodium-glucose cotransporter-2 inhibitors (SGLT-I) as first-line medications after metformin.
Methods Data were obtained in 2015 from Intego, a morbidity registration network of 111 general practitioners (GPs) working in 48 practices and including 123 261 registered patients.
Results Of 123 261 patients, 9616 had T2D. Of these patients, 4200 (43.7%) presented with ASCVD and/or CKD and/or HF. Specifically, 3348 (34.8%) patients had ASCVD, 388 (4.0%) had heart failure, and 1402 (14.6%) had CKD. Compared to patients without any of these comorbidities, patients with at least 1 of these conditions were older (69.7 ±12.6 vs. 63.1±12.5 years), had higher LDL-C values (104.2±35.8 mg/dl vs. 97.2±37.7) and less frequently achieved the systolic blood pressure target of 140 mm Hg (53 vs. 61%) (all p<0.001). Comorbid patients also had significantly more other comorbidities, such as dementia or cancer; received more recommended medications, such as statins; and received less metformin. Most patients with HF (325; 3.4%) had ASCVD (114; 1.2%), CKD (76; 0.8%), or both (135; 1.4%). In total, 478 patients with CKD (5.0%) also had ASCVD.
Conclusions At the primary care level, 44% of T2D patients suffer from ASCVD, CKD, and/or HF, and thus qualify for GLP-1RA or SGLT2-I therapy.
Publication History
Received: 11 February 2021
Received: 16 April 2021
Accepted: 26 April 2021
Article published online:
21 June 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Yang W, Dall TM, Beronjia K. et al. Economic costs of diabetes in the U.S. in 2017. Diabetes Care 2018; 41: 917-28 DOI: 10.2337/dci18-0007.
- 2 Di Angelantonio E, Kaptoge S, Wormser D. et al. Association of cardiometabolic multimorbidity with mortality. J Am Med Assoc 2015; 314 DOI: 10.1001/jama.2015.7008.
- 3 Cubbon RM, Adams B, Rajwani A. et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res 2013; 10: 330-336 DOI: 10.1177/1479164112471064.
- 4 Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29-34 DOI: 10.1016/0002-9149(74)90089-7.
- 5 Davies MJ, D’Alessio DA, Fradkin J. , et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 2012: dci180033 DOI: 10.2337/DCI18-0033.
- 6 Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Investig 2014; 124: 2333-2340 DOI: 10.1172/JCI72271.
- 7 Gheith O, Othman N, Nampoory N. , et al. Diabetic kidney disease: difference in the prevalence and risk factors worldwide. J Egypt Soc Nephrol Transplanta 2016; 16: 65 DOI: 10.4103/1110-9165.197379.
- 8 Mann JFE, Ørsted DD, Brown-Frandsen K. et al. Liraglutide and renal outcomes in Type 2 diabetes. N Eng. J Med 2017; 377: 839-848 DOI: 10.1056/NEJMoa1616011.
- 9 Marso SP, Bain SC, Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Eng. J Med 2016; 375: 1834-1844 DOI: 10.1056/NEJMoa1607141.
- 10 Gerstein HC, Colhoun HM, Dagenais GR. et al. Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial. The Lancet 2019; 394: 131-138 DOI: 10.1016/S0140-6736(19)31150-X.
- 11 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Eng J Med 2015; 373: 2117-2228 DOI: 10.1056/NEJMoa1504720.
- 12 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Eng. J Med 2017; 377: 644-657 DOI: 10.1056/NEJMoa1611925.
- 13 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Eng J Med 2019; 380: 2295-2306 DOI: 10.1056/NEJMoa1811744.
- 14 Bae JH, Park EG, Kim S. et al. Effects of sodium-glucose cotransporter 2 inhibitors on renal outcomes in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Sci Rep 2019; 9: 1-9 DOI: 10.1038/s41598-019-49525-y.
- 15 Buse JB, Wexler DJ, Tsapas A. et al. 2019 Update to: Management of hyperglycemia in Type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020; 43: 487-493 DOI: 10.2337/dci19-0066.
- 16 Care D, Suppl SS. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2020. Diabetes Care 2020; 43: S98-S110 DOI: 10.2337/dc20-S009.
- 17 Care D, Suppl SS. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2020. Diabetes Care 2020; 43: S111-S34 DOI: 10.2337/dc20-S010.
- 18 Truyers C, Goderis G, Dewitte H. et al. The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project. BMC Med Inform Decis Mak 2014; 14: 48 DOI: 10.1186/1472-6947-14-48.
- 19 World Organization of National Colleges Academies and Academic Associations of General Practitioners/Family Physicians. ICPC-2 international classification of primary care. Oxford Medical Publications 1998
- 20 Vaes B, Beke E, Truyers C. et al. The correlation between blood pressure and kidney function decline in older people: A registry-based cohort study. BMJ Open 2015; 5: e007571 DOI: 10.1136/bmjopen-2015-007571.
- 21 Stone NJ, Robinson JG, Lichtenstein AH. et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: Synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Int Med 2014; 160: 339-343
- 22 KDIGO. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements 2013; 3: 136-50 DOI: 10.1038/kisup.2012.76.
- 23 McGurnaghan S, Blackbourn LAK, Mocevic E. et al. Cardiovascular disease prevalence and risk factor prevalence in Type 2 diabetes: a contemporary analysis. Diabet Med 2019; 36: 718-725 DOI: 10.1111/dme.13825.
- 24 Lautsch D, Wang T, Yang L, Rajpathak SN. Prevalence of established cardiovascular disease in patients with type 2 diabetes mellitus in the UK. Diabetes Ther 2019; 10: 2131-2137 DOI: 10.1007/s13300-019-00698-9.
- 25 Rungby J, Schou M, Warrer P. et al. Prevalence of cardiovascular disease and evaluation of standard of care in type 2 diabetes: a nationwide study in primary care. Cardiovasc Endocrinol 2017; 6: 145-151 DOI: 10.1097/XCE.0000000000000135.
- 26 Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 2018; 17: 1-19 DOI: 10.1186/s12933-018-0728-6.
- 27 Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: An updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging. BMC Res Notes 2014; 7: 1-7 DOI: 10.1186/1756-0500-7-415.
- 28 Detournay B, Simon D, Guillausseau PJ. et al. Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes Metab 2012; 38: 102-112
- 29 Deaton C, Benson J. Time for correct diagnosis and categorisation of heart failure in primary care. Br J Gen Pract 2016; 66: 554-555 DOI: 10.3399/bjgp16X687649.
- 30 Van Riet EES, Hoes AW, Limburg A. et al. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014; 16: 772-777 DOI: 10.1002/ejhf.110.